Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Dr. Reddy's delivered a strong Q4 FY25 with consolidated revenue of INR 8,506 crore (+20% YoY) and EBITDA of INR 2,475 crore (+32% YoY), driven by the NRT acquisition and broad-based generic growth. EBITDA margin expanded 267 bps YoY to 29.1%, despite a 300 bps gross margin decline from one-off manufacturing costs and lower milestone income. The North America generics business grew 7% YoY to $418M, while Europe surged 142% YoY to EUR 140M, boosted by NRT. Management guided for double-digit revenue growth in FY26 and stable margins, with REVLIMID exclusivity ending in January 2026. Key growth drivers include semaglutide launches in Canada/India in CY2026, biosimilar progress (abatacept filing by end-2025), and continued BD. Risk: potential U.S. tariffs on generics could pressure margins, though management is working with customers to mitigate supply disruptions.
डॉ. रेड्डीज ने वित्त वर्ष 2025 की चौथी तिमाही में मजबूत प्रदर्शन किया। कंपनी की कुल आय 8,506 करोड़ रुपये रही, जो पिछले साल से 20% ज्यादा है। कमाई (EBITDA) 2,475 करोड़ रुपये रही, जो 32% बढ़ी। यह वृद्धि NRT कंपनी खरीदने और जेनेरिक दवाओं की बिक्री बढ़ने से हुई। मुनाफा मार्जिन 29.1% रहा, जो पिछले साल से 2.67% ज्यादा है। उत्तरी अमेरिका में जेनेरिक दवाओं की बिक्री 7% बढ़कर 418 मिलियन डॉलर हुई। यूरोप में बिक्री 142% बढ़कर 140 मिलियन यूरो पहुंची। कंपनी को अगले साल भी अच्छी वृद्धि की उम्मीद है। जनवरी 2026 में REVLIMID दवा का एकाधिकार खत्म होगा। नए विकास में कनाडा और भारत में semaglutide दवा लॉन्च करना शामिल है। जोखिम: अमेरिकी टैरिफ से मुनाफा कम हो सकता है।
Promises0 met · 2 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
U.S. tariffs on generics
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
North America Generics Revenue
$418M
+7% YoY
Q4 FY25 revenue driven by volume growth and new launches, partially offset by low single-digit price erosion.
Europe Generics Revenue
EUR 140M
+142% YoY
Strong growth from NRT acquisition and base business; ex-NRT growth was 29% YoY.
India Business Revenue
INR 1,305 crore
+16% YoY
Double-digit growth driven by new launches and pricing; ex-vaccine growth was 6%.
Global Generic Filings (FY25)
249
N/A
Completed 95 filings in Q4; pipeline includes complex generics, biosimilars, and GLP-1.
What Changed vs Last Quarter
NEW
Double-digit revenue growth in FY26
Management expects double-digit revenue growth for FY2026, including contributions from new launches and biosimilars, despite REVLIMID exclusivity ending in January 2026.
NEW
EBITDA margin maintained at ~28% in FY26
Management guided for EBITDA margins to remain around 28% in FY2026, similar to FY2025 levels, through productivity measures and revenue growth.
NEW
Abatacept filing by end of CY2025
Phase III trials ongoing; submission planned for end of 2025, with IV launch expected immediately after patent expiry and sub-Q launch a year later.
UPDATED
Semaglutide launch in Canada and India in CY2026
Management confirmed plans to launch generic semaglutide in Canada and India during calendar 2026, pending IP landscape and regulatory approvals.
DROPPED
R&D spend guidance of 8.5%-9% for FY25
Management expects full-year R&D investment to be in the range of 8.5% to 9% of sales.
DROPPED
Abatacept biosimilar filing in December 2025
Plans to file abatacept biosimilar in the US by December 2025, with potential launch in January 2027.
DROPPED
SG&A expenses to remain around 28% of sales
Management indicated SG&A as a percentage of sales will stay at current levels (~28%) going forward.
NEW RISK
U.S. tariffs on generics
Potential tariffs on pharmaceutical imports could impact margins; management is working with customers to ensure supply continuity but uncertainty remains.
NEW RISK
REVLIMID revenue cliff in January 2026
Exclusivity ends in January 2026, leading to significant revenue decline; management expects to offset through growth in other segments but risk remains.
NEW RISK
Gross margin volatility from one-off costs
Q4 gross margin fell 300 bps due to manufacturing overhead and lower milestone income; while management considers it one-off, recurrence could pressure margins.
NEW RISK
Semaglutide competition in Canada
Multiple players may launch generic semaglutide in Canada, leading to price erosion and lower-than-expected market share for Dr. Reddy's.
RISK GONE
US FDA Form 483 at CTO2 facility
The US FDA issued a Form 483 with seven observations at the CTO2 facility in Bollaram, Hyderabad. Management has responded but resolution timeline is uncertain.
RISK GONE
Lenalidomide revenue decline post-2025
Lenalidomide revenue is expected to decline significantly after September-October 2025 as volume restrictions end and competition intensifies.
RISK GONE
Iron sucrose approval delay due to CRL
The company received a complete response letter (CRL) on the API side for iron sucrose, delaying the expected launch.
RISK GONE
India business underperformance in cardiac and GI segments
Cardiac and gastrointestinal therapy areas are growing slower than the market; management expects recovery but timeline is uncertain.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q1 FY25, Q2 FY24, Q3 FY24, Q4 FY24
Pricing pressure in some key products partially offset volume gains in North America.
Mentioned in Q1 FY25, Q2 FY25, Q3 FY25, Q4 FY24
Management expects full-year R&D investment to be in the range of 8.5% to 9% of sales.
Mentioned in Q2 FY24, Q2 FY25
Management guided that the Abatacept biosimilar is expected to launch in early calendar 2027, with phase III trials nearly complete.
Mentioned in Q1 FY24, Q3 FY25
Lenalidomide revenue is expected to decline significantly after September-October 2025 as volume restrictions end and competition intensifies.
Mentioned in Q2 FY24, Q3 FY25
Management indicated SG&A as a percentage of sales will stay at current levels (~28%) going forward.
Fast read
Guidance and risk preview
Management expects double-digit revenue growth for FY2026, including contributions from new launches and biosimilars, despite REVLIMID exclusivity...
Potential tariffs on pharmaceutical imports could impact margins; management is working with customers to ensure supply continuity but uncertainty...
View Risks →